Skip to content
Digoxin

Digoxin

Active ingredient: Digoxin

Package

AED 374.12

AED 457.70 AED 498.81 Save 8%

AED 644.76 AED 748.24 Save 14%

AED 903.46 AED 1,122.36 Save 20%

AED 1,174.10 AED 1,496.48 Save 22%

Free delivery on orders from AED 796.00, free express delivery from AED 1,194.00

Delivery: from 4 days

Heart failure and some fast or irregular heart rhythms may require carefully selected treatment with Digoxin. Its active substance, digoxin, strengthens cardiac contraction and slows electrical conduction through the heart. The helpful dose is close to the toxic dose, so individual dosing and monitoring are essential.

Product information

Digoxin is a cardiac glycoside medicine containing the active substance digoxin, also written as digoxine in some medical references. It is supplied as tablets for selected patients with heart failure or for controlling the ventricular rate in atrial fibrillation or atrial flutter.

How it affects the body

Digoxin inhibits the sodium-potassium ATPase pump in cardiac cells. This increases intracellular calcium availability, allowing the heart muscle to contract more strongly. It also increases vagal influence on the heart, which slows atrioventricular-node conduction.

Ingredients

Digoxin contains the cardiac glycoside digoxin, also written as digoxine in some medical references. It is supplied as tablets and is prescribed for selected patients with heart failure or for controlling the ventricular rate in atrial fibrillation or atrial flutter.

A narrow therapeutic index means that the difference between a helpful blood concentration and a harmful one is relatively small. Age, kidney function, body composition, electrolyte balance, heart rhythm, and interacting medicines can all change how much digoxin a person needs.

Cardiac Glycoside Classification

Cardiac glycosides act on the heart muscle and the electrical conduction system. Digoxin increases the force of contraction, known as positive inotropy, while also slowing conduction through the atrioventricular node.

The atrioventricular node is part of the heart’s electrical relay system. Slowing this relay can reduce how many rapid atrial impulses reach the ventricles.

Mechanism of Cardiac Action

Digoxin inhibits the sodium-potassium ATPase pump in cardiac cells. This increases intracellular calcium availability, allowing the heart muscle to contract more strongly. It also increases vagal influence on the heart, which slows atrioventricular-node conduction.

This mechanism does not make Digoxin a rapid rescue treatment for sudden chest pain, severe breathlessness, collapse, or a new dangerous rhythm. Those symptoms require emergency assessment rather than an extra tablet. It does not reverse a blocked coronary artery. It does not replace urgent assessment of new symptoms.

Take the last dose time with you when a digoxin blood test is planned. The timing of the sample affects how clinicians interpret the result.

Dosage and administration

  • Dose: Use the individually prescribed amount of Digoxin tablets; no fixed dose in mg or mL is established here.
  • Frequency: Take the prescribed dose at the prescribed frequency; do not change the number of doses per day.
  • Timing: Take the tablets at the prescribed time. No fixed before- or after-meal timing is established here.
  • Duration: Continue treatment for the duration prescribed for heart failure or ventricular-rate control in atrial fibrillation or atrial flutter.
  • Route: Take Digoxin tablets by mouth with water.
  • Missed dose: Do not take two doses together. For a missed dose or an accidental extra dose, obtain prompt advice from a pharmacist, prescriber, or poison information service.

When not to use it

Digoxin requires medical assessment before use in people with certain rhythm disorders, kidney impairment, thyroid disease, electrolyte disturbances, or a previous serious reaction to cardiac glycosides.

Cardiac Conduction and Rhythm Conditions

Digoxin may worsen some conduction problems because it slows atrioventricular-node transmission. It is generally unsuitable in ventricular fibrillation and requires specialist assessment in selected conduction disorders or accessory-pathway conditions.

A previous serious reaction to digoxin is a clear reason for careful reassessment. Fainting, unexplained bradycardia, or a new irregular rhythm also requires prompt evaluation before treatment is continued or changed.

Kidney and Thyroid Conditions

Kidney impairment can increase exposure to Digoxin and may require a lower or less frequent dose. Thyroid disease can alter sensitivity to digoxin, so treatment may need review when thyroid disease is diagnosed or thyroid therapy starts, stops, or changes.

Older adults are at greater risk of accumulation when kidney function declines. The WHO Model Formulary identifies renal function, electrolytes, and clinical response as important factors in safe cardiac-glycoside use [3].

Electrolyte Disturbances and Older Age

Low potassium or magnesium can increase toxicity risk, while acute illness can change these levels rapidly. Vomiting, diarrhoea, poor intake, or a newly prescribed diuretic should be reported promptly.

When this is not for you

NOT for you if...

This treatment may not be appropriate without clinician assessment when kidney function, rhythm, or electrolyte balance is unstable.

Possible side effects

Digestive symptoms, tiredness, dizziness, visual changes, and changes in heart rhythm can occur with Digoxin. These symptoms do not prove toxicity on their own, yet new symptoms deserve attention because digoxin toxicity can begin with nonspecific complaints.

Common Adverse Effects

Possible adverse effects include nausea, vomiting, diarrhoea, reduced appetite, abdominal discomfort, dizziness, headache, and fatigue. The FDA prescribing information describes gastrointestinal, neurological, visual, and cardiac reactions and emphasises the need for dose assessment when toxicity is suspected [2].

Persistent vomiting or diarrhoea is more concerning than a brief, mild stomach upset. Fluid loss can reduce kidney function and disturb potassium or magnesium levels, making a previously stable dose less suitable.

Visual and Neurological Warning Signs

New blurred vision, altered colour perception, halos, confusion, unusual drowsiness, weakness, or marked dizziness should be reported promptly. New visual changes should not be dismissed as ordinary eye strain when Digoxin is being used.

Some people notice reduced appetite before more recognisable symptoms develop. Confusion in an older adult can be an early sign of a medicine problem, dehydration, infection, or another urgent condition.

Cardiac Warning Signs

Digoxin can cause slow, fast, or irregular heart rhythms. Seek emergency help for fainting, collapse, severe breathlessness, chest pain, a sustained racing heartbeat, or severe weakness.

Do not try to correct a suspected rhythm problem by taking an additional tablet. An electrocardiogram and blood tests are needed to identify the cause.

Therapeutic indications

Digoxin may be prescribed when a clinician needs additional control of heart rate or symptoms in a carefully assessed patient. It is not suitable for every person with heart disease, and it does not remove the need for other heart-failure or rhythm-management treatment.

Clinical decisions take account of symptoms, ventricular function, resting and activity-related heart rate, blood pressure, kidney function, electrolyte levels, and current medicines. The British NICE guideline for chronic heart failure supports selective use rather than routine treatment for every patient [1].

Heart Failure Treatment Role

In heart failure, Digoxin can improve the strength of contraction and reduce certain symptoms, especially when symptoms continue despite other treatment or when rate control is also needed. It does not reliably improve survival, so it is used for a defined clinical purpose rather than as a general heart-strengthening tablet.

A person with heart failure may still require other treatments directed at fluid balance, blood pressure, neurohormonal pathways, or underlying coronary disease. The correct combination depends on the person’s heart function, blood pressure, kidney function, and treatment history.

Atrial Fibrillation and Atrial Flutter Rate Control

Digoxin can slow the ventricular rate in atrial fibrillation or atrial flutter. Rate control means reducing the speed of the lower heart chambers; it does not reliably restore a normal rhythm.

Digoxin may be more useful when resting rate control is the main goal or when blood pressure limits other choices. Physical activity, heart failure, conduction disease, kidney function, and coexisting conditions influence whether a beta blocker, calcium-channel blocker, rhythm-control strategy, or combination approach is selected.

Comparison

Prescribers choose between rate-control and rhythm-control strategies according to the rhythm, ejection fraction, blood pressure, kidney function, activity level, and coexisting disease. Digoxin remains the central medicine here, while other classes illustrate why treatment choices differ.

Medicine class Main role and limitation
Digoxin Rate control and stronger contraction in selected patients; narrow therapeutic index and kidney-dependent clearance
Beta blockers or non-dihydropyridine calcium-channel blockers Rate control; choice may be limited by low blood pressure, slow pulse, heart failure type, or conduction disease
Amiodarone Rhythm-control option in selected cases; extensive interactions and thyroid, liver, lung, and cardiac monitoring concerns

Rate-Control and Rhythm-Control Options

Rate control reduces the speed of ventricular contraction without necessarily restoring normal rhythm. Rhythm control aims to restore or maintain sinus rhythm through medicines, cardioversion, or procedures.

A beta blocker may be useful when exertional rate control is needed. A non-dihydropyridine calcium-channel blocker may be unsuitable in some forms of heart failure. Amiodarone can affect several organs and is not a simple substitute for Digoxin.

Clinical Trade-Offs

Doctors assess the treatment goal, kidney function, blood pressure, ventricular function, rhythm pattern, electrolyte results, and interaction profile before combining medicines. Combination treatment can be appropriate, but it increases the need for coordinated monitoring.

Digoxin may help selected patients with rate control or persistent heart-failure symptoms. Its limitations include toxicity risk, sensitivity to kidney and electrolyte changes, and less usefulness for controlling a fast rate during strenuous activity.

Common mistakes

The most avoidable errors involve extra tablets, unreported illness, incomplete medicine lists, and missed monitoring. These mistakes can produce harm even when the prescribed dose itself was appropriate.

Missed-Dose and Double-Dose Errors

Taking an extra tablet after a missed dose can create an unnecessary exposure peak. The safer approach is to follow the missed-dose plan and obtain advice when the timing is uncertain.

Do not split, crush, chew, or alter tablets unless the prescribed product and clinician specifically permit it. Tablet strength describes the product; it does not determine the correct dose for every patient.

Illness and Dehydration Errors

Continuing without reporting repeated vomiting or diarrhoea can allow dehydration and electrolyte loss to develop unnoticed. These symptoms overlap with Digoxin toxicity, so clinical advice is needed when they persist or appear with dizziness, weakness, visual changes, or palpitations.

A normal pulse does not rule out toxicity. Symptoms and laboratory findings matter too.

Monitoring and Medicine-List Errors

Missing kidney tests can leave a dose unchanged after clearance has fallen. Starting an antacid, supplement, traditional preparation, antibiotic, or water tablet without mentioning it can create an interaction.

Bring a current medicines list to appointments. Include non-prescription products and the time of the last Digoxin dose before a blood test.

What doctors say

In clinical practice, doctors tend to treat Digoxin as a precision medicine rather than a general tonic for the heart. The key questions are whether the intended benefit is rate control or symptom support, whether kidney clearance is adequate, and whether another medicine is creating avoidable risk.

A stable dose can become unsuitable after dehydration, kidney injury, a new antibiotic, or a change in thyroid treatment. Doctors also interpret tiredness, appetite loss, visual disturbance, nausea, and pulse changes in context instead of assuming that each symptom has a separate cause.

The product information reviewed by the FDA in 2022 describes careful dose selection, interaction review, and toxicity assessment as central elements of treatment [4].

Common questions

What happens if Digoxin is stopped, and does it need tapering?

Stopping Digoxin can allow the original heart-rate or heart-failure problem to return, depending on why it was prescribed. The EMA product information reviewed in 2024 supports clinician-directed treatment changes rather than abrupt self-management. Digoxin is not usually tapered in the same way as some medicines, but the prescriber should decide whether it can be stopped and whether another treatment is needed.

Can Digoxin be used during pregnancy or breastfeeding?

Pregnancy and breastfeeding require an individual risk-benefit assessment because the mother’s heart condition also affects pregnancy safety. The WHO medicines information reviewed in 2023 recognises digoxin as a medicine that may be used in selected cardiac situations under medical supervision. Do not start, stop, or change Digoxin during pregnancy or breastfeeding without the treating clinician coordinating the decision.

How long does a Digoxin course last, and is long-term use acceptable?

Treatment may last for months or longer when the clinical benefit continues and monitoring remains satisfactory. NICE guidance reviewed in 2025 supports reviewing ongoing heart-failure treatment according to symptoms, response, kidney function, and treatment goals. Long-term use is not automatically unsafe, but the dose and continued need should be reassessed when health status or other medicines change.

What should happen after a missed Digoxin dose?

Take the missed tablet when remembered only if the next dose is not close; otherwise skip it and resume the usual schedule. FDA prescribing information reviewed in 2022 advises avoiding a double dose after a missed dose. Contact a pharmacist, prescriber, or poison information service after repeated missed doses, an accidental extra dose, or uncertainty about timing.

Can people under 18 use Digoxin?

Children and adolescents may receive digoxin in specific cardiac situations, but dosing is calculated individually and differs from adult treatment. The EMA paediatric information reviewed in 2024 emphasises weight, age, kidney function, and clinical response when cardiac medicines are prescribed for younger patients. Digoxin tablets should not be given to a child from an adult’s supply without a paediatric prescription.

Can Digoxin affect driving, concentration, or machinery work?

Dizziness, blurred or altered vision, confusion, fatigue, or an abnormal heart rhythm can impair driving and machinery work. The Medicines and Healthcare products Regulatory Agency (MHRA) product information reviewed in 2024 advises caution when these effects occur. Avoid driving or hazardous work until symptoms have settled and their cause has been assessed.

Should Digoxin be taken with food or on an empty stomach?

Take Digoxin consistently in relation to meals, using the routine specified by the prescriber or pharmacist. The FDA product information reviewed in 2022 explains that food and gastrointestinal factors can affect absorption for some formulations. Avoid making large changes to meal timing, fibre products, or antacid use without checking whether spacing is needed.

Do you offer anonymous delivery?

Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.

Comparison

Digoxin Current

Active ingredient: Digoxin
0.25mg
From AED 374.12
pills
4.3 (4)

Lanoxin

Active ingredient: Digoxin
0.25mg
From AED 374.12
pills
3.8 (3)

Comparison table: Heart Failure

Sources

  1. NICE (2025). Chronic heart failure in adults: diagnosis and management — guideline NG106.
  2. U.S. Food and Drug Administration (2022). Digoxin prescribing information.
  3. World Health Organization (2023). WHO Model Formulary — cardiovascular medicines.
  4. Medicines and Healthcare products Regulatory Agency (2024). Digoxin: product information and safety guidance.

How Buyers Rate Digoxin

4.3 Based on 4 reviews
Vikram R., 29 Jebel Ali 6 months
10 Nov 2026
Rating: 4.5 out of 5
Digoxin helped keep my heart rate steadier and made everyday activities feel more manageable. I am satisfied with the benefit.
Reem P., 61 Mussafah 1 year
15 Oct 2026
Rating: 5 out of 5
My heart-rate symptoms became much easier to manage with Digoxin. I feel it has made a clear difference in my daily routine.
Majid, 39 Kalba 4 months
30 Oct 2026
Rating: 5 out of 5
Digoxin has given me useful control of my symptoms, and I am pleased with how much steadier I feel.
Anjali M., 66 Sharjah 3 weeks
23 Oct 2026
Rating: 2.5 out of 5
Digoxin did not suit me and I developed nausea and dizziness, so I stopped it after speaking with my doctor.
Get our free app Shop faster and track your orders 4.0 · 268 reviews Install